John Gordon McVie
Vorstandsvorsitzender bei Cancer Intelligence Ltd.
Profil
John Gordon McVie is currently the Chief Executive Officer at Cancer Intelligence Ltd., Director at Nanovi Radiotherapy A, Principal at American Society of Clinical Oncology, Inc., and Principal at American Association for Cancer Research.
In the past, he was a Director at Cyclacel Group Plc and Cyclacel Pharmaceuticals, Inc., Joint Director General at Cancer Research UK, Director General at The Cancer Research Campaign, and Clinical Research Director at Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh.
Aktive Positionen von John Gordon McVie
Unternehmen | Position | Beginn |
---|---|---|
Cancer Intelligence Ltd. | Vorstandsvorsitzender | - |
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | Direktor/Vorstandsmitglied | - |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | - |
American Society of Clinical Oncology, Inc.
American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von John Gordon McVie
Unternehmen | Position | Ende |
---|---|---|
CYCLACEL PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 10.02.2009 |
Cyclacel Group Plc
Cyclacel Group Plc Pharmaceuticals: MajorHealth Technology Cyclacel Group Plc designs and develops small molecule drugs. The company developed small molecule drugs act on key cell cycle regulators to stop uncontrolled cell division in cancer and other diseases involving abnormal cell proliferation. Cyclacel Group Plc was founded by Professor Sir David Lane in 1996 and is headquartered in Dundee, UK. | Direktor/Vorstandsmitglied | 15.10.2008 |
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh Investment Trusts/Mutual FundsMiscellaneous Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek is a scientific research institute and a specialist clinic. The firm’s areas of research are including fundamental, clinical and translational cancer research. The company was founded in 1916 and is headquartered in Amsterdam, Netherlands. | Technik-/Wissenschafts-/F&E-Leiter | - |
The Cancer Research Campaign | Corporate Officer/Principal | - |
Cancer Research UK
Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CYCLACEL PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 8 |
---|---|
Cyclacel Group Plc
Cyclacel Group Plc Pharmaceuticals: MajorHealth Technology Cyclacel Group Plc designs and develops small molecule drugs. The company developed small molecule drugs act on key cell cycle regulators to stop uncontrolled cell division in cancer and other diseases involving abnormal cell proliferation. Cyclacel Group Plc was founded by Professor Sir David Lane in 1996 and is headquartered in Dundee, UK. | Health Technology |
American Society of Clinical Oncology, Inc.
American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Health Services |
Cancer Research UK
Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Commercial Services |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Commercial Services |
Cancer Intelligence Ltd. | |
The Cancer Research Campaign | Finance |
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh Investment Trusts/Mutual FundsMiscellaneous Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek is a scientific research institute and a specialist clinic. The firm’s areas of research are including fundamental, clinical and translational cancer research. The company was founded in 1916 and is headquartered in Amsterdam, Netherlands. | Miscellaneous |
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | Health Technology |